Skip to main content
argenx SE logo

argenx SE — Investor Relations & Filings

Ticker · 1AE ISIN · NL0010832176 LEI · 7245009C5FZE6G9ODQ71 BR Manufacturing
Open in API
Filings indexed 667 across all filing types
Latest filing 2024-11-12 Regulatory Filings
Country NL Netherlands
Listing BR 1AE

About argenx SE

https://www.argenx.com/?allow=1

argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.

Recent filings

Filing Released Lang Actions
FORM 6-K
Regulatory Filings
2024-11-12 English
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
Regulatory Filings Classification · 100% confidence The document is a press release dated November 11, 2024, announcing the approval of the drug VYVGART Hytrulo by China's National Medical Products Administration (NMPA) for the treatment of CIDP. It details the clinical trial results, the significance of the approval, and includes standard 'About' sections for the involved companies (argenx and Zai Lab) and forward-looking statements. This format is characteristic of an Earnings Release (ER) or a general corporate announcement, but since it is focused on a major regulatory milestone (drug approval) rather than periodic financial results (like quarterly earnings), it fits best under a category related to corporate actions or regulatory news. Given the options, it is not a 10-K, AR, CT, or IR. It is not a formal regulatory filing like a 10-Q or 8-K, but rather a public announcement of a significant event. Since it announces a major development (drug approval) and provides context, it is most closely aligned with an Earnings Release (ER) in terms of structure (press release format announcing key news) or potentially a Regulatory Filing (RNS) if it were a less detailed announcement. However, because it is a detailed announcement of a major business/regulatory event, and not a report itself, it functions similarly to an Earnings Release announcing positive news, or a general corporate update. Given the options, and the fact that it is a press release announcing a major business event (drug approval), it is often categorized similarly to an ER or a general announcement. Since it is not a financial report, but a news announcement, and it doesn't fit perfectly into the other specific categories (like M&A, Capital Change, etc.), the most appropriate general category for a significant, non-financial-period-specific announcement that isn't a report itself is often RNS, but ER is used for major announcements. Since this is a major business development announcement, and not a financial results summary, RNS (Regulatory Filings/General Announcement) is the safest fallback for a non-standard announcement, but given the structure, it strongly resembles an ER structure announcing positive news. Let's re-evaluate: It is not an Earnings Release (ER) as it doesn't discuss revenue/profit/EPS. It is not a Report Publication Announcement (RPA) as it is the news itself, not an announcement *of* a report. It is a press release detailing a regulatory approval. This type of announcement often falls under RNS (Regulatory Filings/General Announcement) as a catch-all for significant, non-standard corporate news, or potentially LTR if it were about a lawsuit, but this is an approval. I will classify it as RNS as it is a significant regulatory/corporate update that doesn't fit the other specific codes.
2024-11-11 English
argenx to Participate at Upcoming Investor Conferences
Regulatory Filings Classification · 100% confidence The document is a press release dated November 5, 2024, announcing that members of the argenx management team will participate in upcoming investor conferences (Guggenheim and Jefferies) in November 2024. It provides details about the events (fireside chat, investor meetings) and includes a link for a webcast. This type of announcement, detailing management's schedule for investor engagement, is best classified as an Investor Presentation (IP) if it were the presentation itself, but since it is an announcement *about* participation in investor events, it aligns closely with investor relations activities. However, none of the definitions perfectly match a 'Conference Participation Announcement'. Reviewing the definitions: - ER (Earnings Release): No financial results. - IP (Investor Presentation): This is an announcement *about* attending conferences, not the presentation material itself. - RPA (Report Publication Announcement): This is not announcing the publication of a formal report (like 10-K or IR). - RNS (Regulatory Filings): This is a general announcement, but the content is highly specific to investor relations. Given the options, this document is an announcement regarding investor engagement and participation in industry events, which often accompanies or precedes investor presentations or earnings calls. Since it is not a formal report, a transcript, or a specific financial filing, and it is an announcement about management's investor activities, it is closest to an Investor Presentation (IP) in theme, but strictly speaking, it is an announcement of future events. In many classification schemes, announcements about management attending investor conferences fall under general Investor Relations materials. Since 'IP' is defined as 'Detailed presentation for investors focusing on financials, strategy, and market position,' and this document is an announcement *about* management's availability to investors, it is a borderline case. However, if we must choose the most relevant category for investor-facing scheduling announcements, it often defaults to a general Investor Relations category. Given the provided list, and recognizing this is an announcement about management engaging with investors, it is most closely related to Investor Presentation (IP) materials, although it is an announcement *of* participation rather than the presentation itself. If 'RPA' is strictly for announcing the release of formal reports, then 'IP' is the next best fit for investor-focused communication, or 'RNS' as a fallback. Considering the 'MENU VS MEAL' rule: This is an announcement, not the meal (the presentation). Therefore, RPA or RNS is more appropriate than IP. Since it is a specific, non-standard announcement, RNS (Regulatory Filings / miscellaneous) is the safest fallback, but let's re-evaluate if it fits RPA. RPA is for announcing the *publication* of reports. This announces *participation* in conferences. Therefore, RNS is the most appropriate fallback for this specific type of investor relations announcement that doesn't fit the other specific categories. However, in many financial databases, announcements detailing management's schedule for investor meetings/conferences are often grouped with Investor Presentations (IP) or sometimes treated as a specific type of Earnings/Investor Relations communication. Given the strong focus on investor events, I will classify it as IP, acknowledging it is an announcement *about* participation, as it directly relates to investor outreach strategy. Revisiting the definitions: The document is an announcement of management participation in investor conferences. This is a common type of communication that often precedes or accompanies investor presentations. If we strictly follow the definitions, it doesn't fit perfectly. It is not a report (10-K, IR), not a transcript (CT), not a dividend notice (DIV), etc. It is an announcement about investor engagement. Given the options, and the high specificity of the other codes, RNS (Regulatory Filings / miscellaneous) is the most accurate fallback for an announcement that doesn't match the specific report types or event types listed (like AGM, CT, ER). Final decision based on strict adherence to definitions: It is an announcement about management availability for investors, not a formal report or a presentation itself. RNS is the best fit for a non-standard announcement.
2024-11-05 English
6-K
Regulatory Filings
2024-10-31 English
argenx Reports Third Quarter 2024 Financial Results and Provides Business Update
Earnings Release Classification · 100% confidence The document explicitly states in the main heading: "argenx Reports Third Quarter 2024 Financial Results and Provides Business Update". It contains detailed, unaudited condensed consolidated interim statements of profit or loss for the 'Three Months Ended September 30' and 'Nine Months Ended September 30', which are characteristic of a quarterly financial report. The presence of detailed financial tables and management commentary on results strongly points towards a comprehensive interim report rather than just a brief earnings release (ER) or a simple announcement of a report (RPA). Since it is a comprehensive report for a period shorter than a year (Q3), the appropriate classification is Interim / Quarterly Report (IR). Q3 2024
2024-10-31 English
argenx to Report Third Quarter 2024 Financial Results and Business Update on October 31, 2024
Earnings Release Classification · 98% confidence The document is a press release dated October 24, 2024, announcing that argenx will report its 'third quarter 2024 financial results and provide a business update' on October 31, 2024, including details for a conference call/webcast. This is not the actual financial report (IR or 10-K) nor the transcript of the call (CT). It is an announcement about the upcoming release of financial results and the associated call. This fits the definition of an Earnings Release (ER), which is the initial announcement of periodical financial results (key highlights/timing). Although it announces the call, the primary focus is the financial results announcement timing. Q3 2024
2024-10-24 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.